CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) presented data today on its research regarding novel synergistic drug combinations for the treatment of cancer at the ASCO-NCI-EORTC Molecular Markers meeting in Hollywood, FL on October 19, 2010. The poster entitled “Systematic Combination Screening Exploits Tumor Biology Networks to Create Context-specific Cytotoxicity”, Short, et.al, explores the association of cancer cell line genotype to combination drug sensitivity as a predictor of synergy and potentially responsive patient populations.
